Arrowstreet Capital, Limited Partnership Adaptimmune Therapeutics PLC Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $34,215 - $82,442	32,586 New	32,586 $48,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $567,859 - $931,097	-68,665 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $21,882 - $28,854	2,100 Added 3.15%	68,665 $815,000
Q1 2018 May 14, 2018	BUY	$7.1 - $11.56 $212,836 - $346,534	29,977 Added 81.93%	66,565 $748,000
Q4 2017 Feb 09, 2018	BUY	$6.68 - $8.74 $244,407 - $319,779	36,588	36,588 $244,000

152M

78.5K

36.5K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $121M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.